ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.
- Mechanism
- Curator reviewed
ARG098 is an anti-Fas IgM monoclonal antibody that specifically targets the Fas (also known as APO-1 and CD95) molecule. The Fas molecule which is expressed and activated on the cell surface of inflammatory synovial cells plays a key role for induction of apoptosis (cell death). Binding of ARG098 to Fas molecule of synovial cells causes apoptosis dramatically followed by reduction of the number of synovial cells and improvement of inflammatory symptoms of rheumatoid arthritis. [Argenes Inc. Press Release]
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Code names
- ARG098
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with ARG098, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account